Media & Press
Resources for journalists and editors
Press kit, quick facts and a direct contact for coverage of the May 21 CCI-001 publication.
Quick facts
Verified details for fast reference. For attributable quotes or interviews, use the contact form below.
- Company
- PharmaMatrix Inc.
- Lead asset
- CCI-001
- Stage
- Phase 1 clinical
- Lead indication
- Bladder cancer
- Expansion indication
- Breast cancer
- Trial ID
- NCT04823897
- Mechanism
- Selective βIII-tubulin inhibition
- IP
- Patents granted: USPTO, CIPO, EPO
- Principal investigator
- Jack A. Tuszynski, Ph.D., D.Sc.
- Publication date
- May 21, 2026
Embargo & confidentiality: The May 21 abstract content is non-confidential and free to cite on or after that date. All other clinical and expansion data remain confidential and are shared only under CDA. Please contact us for the full data package.
Media FAQ
Quick answers on the May 21 abstract, embargo, and press kit usage.
- When can I publish coverage of the May 21 abstract?
- The abstract is non-confidential as of May 21, 2026. You may quote, cite and reproduce its contents from that date onward. Coverage referencing the underlying full data set is embargoed until the data are made public.
- What's in the press kit?
- A press release, company fact sheet, plain-language CCI-001 backgrounder, and a boilerplate paragraph. All files are PDF and may be redistributed unchanged with attribution to PharmaMatrix.
- Can I use PharmaMatrix logos and imagery?
- Yes - for editorial coverage of PharmaMatrix and CCI-001. Do not modify the logo, alter colors, or imply endorsement of unrelated products. Headshots and scientific imagery are available on request.
- Who can I quote?
- On-the-record quotes can be attributed to the PharmaMatrix team or, for scientific commentary, to Principal Investigator Jack A. Tuszynski, Ph.D., D.Sc. Please request quotes via the press contact form below.
- Can I get access to the full data or the embargoed pre-print?
- Yes, under a Confidential Disclosure Agreement (CDA). Use the press contact form and indicate your outlet and deadline.
- Is CCI-001 available to patients today?
- CCI-001 is investigational and only available through the active Phase 1 clinical trial (NCT04823897). It is not approved for general use. Please direct patient inquiries to our Contact page.
- How should I describe the company?
- Use the boilerplate paragraph in the press kit verbatim where possible. The official company name is PharmaMatrix Inc.
Press contact
Journalists and editors - request interviews, comment, or the embargoed data package. The press team will follow up by email.